Remove Clinical Trials Remove Genomics Remove Reagent
article thumbnail

Savran Technologies Inc. Rare Cell Detection Platform Contributes to Successful Clinical Trial for Detecting Breast Cancer Recurrence

The Pharma Data

A paper on the clinical trial results published in JAMA Oncology demonstrates the effectiveness of Savran Tech’s CTC detection technology with real world patients. The trial involved about 200 patients with early stage triple negative breast cancer who received chemotherapy and underwent surgery. “We About This Clinical Trial.

article thumbnail

Casting aside CRISPR scissors and making a point with base editors

pharmaphorum

While achieving the Nobel Prize spotlight would have been enough to impress, CRISPR-Cas9 gene editing is part of a growing list of technologies granted Investigational New Drug (IND) applications with early data from clinical trials supporting its safe use in edited cells re-introduced into a patient.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top 30 New Medical Devices of 2024

XTalks

In a clinical trial, participants demonstrated a 98% success rate after six months post implantation, with arteries widened successfully and no stent fractures observed. The Onclarity HPV reagent pack extraction combo. Once in place, it acts as a scaffold, restoring proper blood flow. Photo courtesy of BD.

article thumbnail

BioSpace Global Roundup, Oct. 15

The Pharma Data

The designation of lanifibranor as a Breakthrough Therapy for the treatment of NASH follows the publication in June 2020 of positive topline results from Inventiva’s NATIVE Phase IIb clinical trial with lanifibranor in NASH patients. The trial plans to evaluate safety, tolerability, cytokine profile and efficacy parameters.

article thumbnail

Regulatory Trends in Cell and Gene Therapies

Advarra

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline. But review issues are not the only problems.

article thumbnail

Top 10 Biotech Trends for 2025

XTalks

For example, antisense oligonucleotide (ASO)-based therapies have gained traction, with 100 Phase I clinical trials initiated and around 25 percent of these advancing to Phase II or Phase III trials in recent years. Furthermore, CRISPR/Cas9 presents a promising avenue for overcoming genetic diseases in the near future.